Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly L Warfield

Showing results (11-20 of 102) with videos related to

Pageof 11
Sort By:
Antiviral Research|February 9, 2008
Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA virusesKevin B Spurgers, C Matthew Sharkey, Kelly L Warfield, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2002
Early response to rotavirus infection involves massive B cell activationSarah E Blutt, Kelly L Warfield, Dorothy E Lewis, et al.
Journal of Virology|January 11, 2008
Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunitySarah E Blutt, Kelly L Warfield, Mary K Estes, et al.
Antiviral Research|August 10, 2020
Iminosugars: A host-targeted approach to combat Flaviviridae infectionsLisa Evans DeWald, Chloe Starr, Terry Butters, et al.
Plos One|March 19, 2015
In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4Eric J Stavale, Hong Vu, Aruna Sampath, et al.
Journal of Virology|June 16, 2006
Active viremia in rotavirus-infected miceSarah E Blutt, Martijn Fenaux, Kelly L Warfield, et al.
Journal of Virology|September 29, 2006
Rotavirus infection enhances lipopolysaccharide-induced intussusception in a mouse modelKelly L Warfield, Sarah E Blutt, Sue E Crawford, et al.
Viruses|May 27, 2023
Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 SuppressionEvelyn J Franco, George L Drusano, Kaley C Hanrahan, et al.
International Journal of Toxicology|March 1, 2022
Investigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral AgentJeffry Shearer, Gary Wolfe, Aruna Sampath, et al.
Vaccine|September 30, 2005
Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs)Sarah E Blutt, Kelly L Warfield, Christine M O'Neal, et al.
Pageof 11

Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
Antiviral Research|February 9, 2008
Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA virusesKevin B Spurgers, C Matthew Sharkey, Kelly L Warfield, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2002
Early response to rotavirus infection involves massive B cell activationSarah E Blutt, Kelly L Warfield, Dorothy E Lewis, et al.
Journal of Virology|January 11, 2008
Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunitySarah E Blutt, Kelly L Warfield, Mary K Estes, et al.
Antiviral Research|August 10, 2020
Iminosugars: A host-targeted approach to combat Flaviviridae infectionsLisa Evans DeWald, Chloe Starr, Terry Butters, et al.
Plos One|March 19, 2015
In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4Eric J Stavale, Hong Vu, Aruna Sampath, et al.
Journal of Virology|June 16, 2006
Active viremia in rotavirus-infected miceSarah E Blutt, Martijn Fenaux, Kelly L Warfield, et al.
Journal of Virology|September 29, 2006
Rotavirus infection enhances lipopolysaccharide-induced intussusception in a mouse modelKelly L Warfield, Sarah E Blutt, Sue E Crawford, et al.
Viruses|May 27, 2023
Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 SuppressionEvelyn J Franco, George L Drusano, Kaley C Hanrahan, et al.
International Journal of Toxicology|March 1, 2022
Investigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral AgentJeffry Shearer, Gary Wolfe, Aruna Sampath, et al.
Vaccine|September 30, 2005
Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs)Sarah E Blutt, Kelly L Warfield, Christine M O'Neal, et al.
Pageof 11